Comparison of the effectiveness of whole-brain radiotherapy plus temozolomide versus whole-brain radiotherapy in treating brain metastases based on a systematic review of randomized controlled trials.

abstract：:Matrix metalloproteinase (MMP)-2 and MMP-9 have been associated with the ability of tumor cells to metastasize because of their capacity to degrade type IV collagen, the main component of basement membrane, and to their elevated expression in malignant tumors. (S)-methyl 6-(benzyloxycarbonylamino)-2-(2-((S)-2,6-dioxo-...

journal_title：Anti-cancer drugs

authors： Chen MH,Cui SX,Cheng YN,Sun LR,Li QB,Xu WF,Ward SG,Tang W,Qu XJ

更新日期：2008-11-01 00:00:00

abstract：:Results are summarized for two phase II studies of docetaxel as first-line therapy for advanced squamous cell carcinoma of the head and neck (SCCHN) and one study of docetaxel as second-line therapy for advanced soft tissue sarcomas. In all three studies, docetaxel was administered at a dose of 100 mg/m2 by intravenou...

journal_title：Anti-cancer drugs

authors： Verweij J

更新日期：1995-07-01 00:00:00

abstract：:A new dosage formulation of 5-fluorouracil incorporated in microspheres (5-FU-MS) was developed for the treatment of peritoneal carcinomatosis. We studied the acute toxicity and side effects of i.p. 5-FU-MS in mice. The 50% lethal dose value for 5-FU-MS was 535.4 mg/kg of 5-FU, which was 2.22 times that of the aqueous...

journal_title：Anti-cancer drugs

authors： Hagiwara A,Sakakura C,Tsujimoto H,Ohgaki M,Imanishi T,Yamazaki J,Sawai K,Takahashi T,Yamamoto A,Muranishi S,Tabata Y,Ikada Y

更新日期：1996-09-01 00:00:00

abstract：UNLABELLED:Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performa...

journal_title：Anti-cancer drugs

authors： Kudelka AP,Winn R,Edwards CL,Downey G,Greenberg H,Dakhil SR,Freedman RS,LoCoco S,Umbreit J,Delmore JE,Arbuck S,Loyer E,Gacrama P,Fueger R,Kavanagh JJ

更新日期：1997-08-01 00:00:00

abstract：:Pancreatic cancer is one of the leading causes of solid carcinoma with the worst survival rate. The reasons for the worst survival rate include the lack of biomarkers for early detection, diagnosis at a late stage, and the limitation of the current therapy. Further study to investigate the underlying molecular mechani...

journal_title：Anti-cancer drugs

authors： Wang L,Wang Z,Huang L,Wu C,Zhang B

更新日期：2019-03-01 00:00:00

abstract：:Adrenocortical tumor (ACT) is a malignancy with a low incidence rate and the current therapy for advanced disease has a limited impact on overall patient survival. A previous study from our group suggested that elevated expression of aurora-A and aurora-B is associated with poor outcome in childhood ACT. Similar resul...

journal_title：Anti-cancer drugs

authors： Borges KS,Andrade AF,Silveira VS,Marco Antonio DS,Vasconcelos EJR,Antonini SRR,Tone LG,Scrideli CA

更新日期：2017-07-01 00:00:00

abstract：:Metastatic meningioma is a rare disease, which has no effective chemotherapy. We report on a treatment of this condition with Doxil, a liposomal doxorubicin formulation. A 60-year-old woman with massive pleuro-pulmonary metastases from recurrent cranial meningioma was treated with Doxil (50-37.5 mg/m2) for 18 months w...

journal_title：Anti-cancer drugs

authors： Travitzky M,Libson E,Nemirovsky I,Hadas I,Gabizon A

更新日期：2003-03-01 00:00:00

abstract：:Antimicrobial peptides of the cathelicidin family play a central role in the host defense system. Our group has reported previously that cathelicidin-related or cathelicidin-modified antimicrobial peptides, such as FF/CAP-18, have antiproliferative effects on the squamous cell carcinoma cell line SAS-H1 and colon canc...

journal_title：Anti-cancer drugs

authors： Kuroda K,Fukuda T,Okumura K,Yoneyama H,Isogai H,Savage PB,Isogai E

更新日期：2013-09-01 00:00:00

abstract：:9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

journal_title：Anti-cancer drugs

authors： Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

更新日期：1998-01-01 00:00:00

abstract：:The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60% of patients but is curative in only about 40-50%. More aggressive and/or dose-intensified chemotherapy regimens have failed to...

journal_title：Anti-cancer drugs

authors： Coiffier B,Pfreundschuh M,Stahel R,Vose J,Zinzani PL

更新日期：2002-11-01 00:00:00

abstract：:Epirubicin is usually administered in combination with other cytotoxics. Few pharmacological studies address whether relevant clinical interactions occur in vitro between these drugs. This study investigated whether epirubicin interacted with other cytotoxics or anti-emetics. The following drugs were prepared at pharm...

journal_title：Anti-cancer drugs

authors： Zhang W,Zalcberg JR,Cosolo W

更新日期：1992-12-01 00:00:00

abstract：:Alpha-tocopheryloxy acetic acid (α-TEA) is an ether derivative of vitamin E and has been shown to suppress tumor growth in various murine and human xenograft tumor models, including melanoma, breast, lung, prostate, and ovarian cancers. The purpose of this study was to assess its safety and pharmacokinetics after repe...

journal_title：Anti-cancer drugs

authors： Hahn T,Akporiaye ET

更新日期：2012-04-01 00:00:00

abstract：:PC cell-derived growth factor is a novel growth factor for tumor formation and progression. No comprehensive literature concerning PC cell-derived growth factor expression status and its biological function in squamous cell carcinoma, especially in the larynx, is, however, available. The target of this study is to eva...

journal_title：Anti-cancer drugs

authors： Kong WJ,Zhang SL,Chen X,Zhang S,Wang YJ,Zhang D,Sun Y

更新日期：2007-01-01 00:00:00

abstract：:Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal cancer patients, provided that they have no activating KRAS mutation in their tumour. Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification of KRAS. We hypothesize that the act...

journal_title：Anti-cancer drugs

authors： Baas JM,Krens LL,Bos MM,Portielje JE,Batman E,van Wezel T,Morreau H,Guchelaar HJ,Gelderblom H

更新日期：2015-09-01 00:00:00

abstract：:Transcatheter arterial chemoembolization (TACE) is widely used to treat unresectable hepatocellular carcinoma (HCC). Recently, a fine-powder formulation of cisplatin (DDP-H) was developed in Japan. We aimed to compare clinical outcomes after TACE using epirubicin or DDP-H in patients with HCC. We evaluated 202 patient...

journal_title：Anti-cancer drugs

authors： Yodono H,Matsuo K,Shinohara A

更新日期：2011-03-01 00:00:00

abstract：:Based on observations of a discrepancy between 'hypersensitivity' reactions to docetaxel (DT) and the clinical features of allergic reactions, we explored the hypothesis that DT-induced acute hypersensitivity reactions (AHRs) have a non-allergic origin. Forty cancer patients receiving DT and 16 patients receiving othe...

journal_title：Anti-cancer drugs

authors： Ardavanis A,Tryfonopoulos D,Yiotis I,Gerasimidis G,Baziotis N,Rigatos G

更新日期：2004-07-01 00:00:00

abstract：:Concurrent and pre-exposure of A431 human epidermoid cancer cells to UCN-01, an investigational anticancer drug, with 5-fluoro--2'-deoxyuridine (FdUrd), which targets thymidylate synthase, produced more than additive cytotoxicty. A 24-h exposure to 10 nM FdUrd led to inhibition of TS, a 2.5-fold increase in total thym...

journal_title：Anti-cancer drugs

authors： Grem JL,Danenberg KD,Kao V,Danenberg PV,Nguyen D

更新日期：2002-03-01 00:00:00

abstract：:Targeting of cytotoxic agents represents a modern approach to the treatment of various cancers, that improves the efficacy and reduces peripheral toxicity. Recently we developed a powerful cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AN-207, designed to be targeted to tumors that express LHRH rece...

journal_title：Anti-cancer drugs

authors： Arencibia JM,Schally AV,Halmos G,Nagy A,Kiaris H

更新日期：2001-01-01 00:00:00

abstract：:Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit th...

journal_title：Anti-cancer drugs

authors： Mastronardi L,Puzzilli F,Ruggeri A

更新日期：1998-08-01 00:00:00

abstract：:There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying unit costs to indivi...

journal_title：Anti-cancer drugs

authors： Franken MG,Leeneman B,Jochems A,Schouwenburg MG,Aarts MJB,van Akkooi ACJ,van den Berkmortel FWPJ,van den Eertwegh AJM,de Groot JWB,van der Hoeven KJM,Hospers GAP,Kapiteijn E,Koornstra R,Kruit WHJ,Louwman MWJ,Piersma D,van

更新日期：2018-07-01 00:00:00

abstract：:Topical treatment of skin metastases with a cytotoxic agent is attractive for its easy self-administration and absence of major systemic interference. Miltefosine exerts its cytotoxicity by acting on cell membrane phospholipids and can be administered topically. Twenty breast cancer patients with progression of skin m...

journal_title：Anti-cancer drugs

authors： Smorenburg CH,Seynaeve C,Bontenbal M,Planting AS,Sindermann H,Verweij J

更新日期：2000-11-01 00:00:00

abstract：:Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer. The risk of secondary leukaemia is well described after mitoxantrone treatment in breast cancer and multiple sclerosis. Recent improvements of systemic chemotherapy increased the median survival in pati...

journal_title：Anti-cancer drugs

authors： Martinez V,Mir O,Dômont J,Bouscary D,Goldwasser F

更新日期：2007-02-01 00:00:00

abstract：:Cyclosporin A (CsA) is a calcium antagonist and can enhance the efficacy of some protein drugs, but its mechanism remains unknown. In this study, MAP30, a ribosome-inactivating protein reported to have apoptotic effects on cancer cells, was fused with S3, an epidermal growth factor receptor (EGFR)-targeting peptide. I...

journal_title：Anti-cancer drugs

authors： Song ZT,Zhang LW,Fan LQ,Kong JW,Mao JH,Zhao J,Wang FJ

更新日期：2018-09-01 00:00:00

abstract：:The antiproliferative effect of simvastatin on tumor cells has been speculated to be by intracellular signal inhibition through 3-hydroxy-3-methylglutaryl acetyl coenzyme A reductase. We examined the killing effect of simvastatin on imatinib-sensitive and resistant chronic myelogenous leukemia (CML) cells (three kinds...

journal_title：Anti-cancer drugs

authors： Oh B,Kim TY,Min HJ,Kim M,Kang MS,Huh JY,Kim Y,Lee DS

更新日期：2013-01-01 00:00:00

abstract：:The cytotoxic effects of Tomudex (TX) were investigated on a panel of 15 human tumor cell lines expressing a spontaneous sensitivity to the tested agent. We determined the basal cellular amount of relevant cellular factors potentially related to the cytotoxic efficacy of or resistance to TX. We selected thymidylate sy...

journal_title：Anti-cancer drugs

authors： Chéradame S,Chazal M,Fischel JL,Formento P,Renée N,Milano G

更新日期：1999-06-01 00:00:00

abstract：:Glioma is a primary intracranial malignant tumor with poor prognosis. In this study, we aimed to develop transferrin (Tf)-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles to deliver temozolomide (TMZ) to glioma and evaluate their efficacy to kill glioma. TMZ-loaded nanoparticles were prepared by nanoprecipi...

journal_title：Anti-cancer drugs

authors： Mao J,Meng X,Zhao C,Yang Y,Liu G

更新日期：2019-07-01 00:00:00

abstract：:Extrachromosomal DNA is the predominant form of gene amplification in human tumors. Hydroxyurea (HU) concentrations of 100-150 microM have been promising in vitro for extrachromosomal DNA elimination. The study objective was to determine the HU dose-concentration relationship in nude mice with HU doses from 0 to 200 m...

journal_title：Anti-cancer drugs

authors： Van den Berg CL,McGill JR,Kuhn JG,Walsh JT,De La Cruz PS,Davidson KK,Wahl GM,Von Hoff DD

更新日期：1994-10-01 00:00:00

abstract：:The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy. We evaluated the clinicopathological/prognostic significance of thymidylate s...

journal_title：Anti-cancer drugs

authors： Zhao HY,Huang H,Hu ZH,Huang Y,Lin SX,Tian Y,Lin TY

更新日期：2012-06-01 00:00:00

abstract：:Docetaxel is a new antimicrotubule agent that induces a predominantly sensory neuropathy that is mild in most patients. This prospective study was performed to determine if corticosteroid co-medication reduces the incidence and severity of docetaxel-induced neuropathy. Two groups of patients treated with docetaxel in ...

journal_title：Anti-cancer drugs

authors： Pronk LC,Hilkens PH,van den Bent MJ,van Putten WL,Stoter G,Verweij J

更新日期：1998-10-01 00:00:00

abstract：:In this study the activity of KW-2149 and two of its metabolites, M-16 and M-18, was measured against cell lines with different types of resistance. The influence of these metabolites and of the exposure time on the cytotoxic efficacy of KW-2149 was investigated. Against the human ovarian carcinoma cell lines, AOvC an...

journal_title：Anti-cancer drugs

authors： Dirix LY,Gheuens EE,van der Heyden S,van Oosterom AT,De Bruijn EA

更新日期：1994-06-01 00:00:00